Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA275)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 2 July 2021Published: 27 February 2013
Apixaban for preventing venous thromboembolism after hip or knee replacement surgery (TA245)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 January 2012
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 June 2015
Artificial intelligence for analysing chest CT images (MIB243)Product type:AdviceProgramme:Medtech innovation briefingPublished: 5 January 2021
ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)Product type:AdviceProgramme:Medtech innovation briefingPublished: 11 March 2016
Dabigatran etexilate for preventing venous thromboembolism after hip or knee replacement surgery (TA157)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 September 2008
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 2 July 2021Published: 15 March 2012
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 December 2014
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 2 July 2021Published: 23 September 2015
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 August 2015
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)Product type:AdviceProgramme:Evidence summaryPublished: 24 May 2016
Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery (TA170)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 April 2009
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 2 July 2021Published: 23 May 2012
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 July 2012
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 June 2013
The geko device for reducing the risk of venous thromboembolism (HTG344)Product type:GuidanceProgramme:HealthTech guidancePublished: 25 June 2014
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 August 2023Published: 26 March 2020
Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)Product type:GuidanceProgramme:NICE guidelineLast updated: 13 August 2019Published: 21 March 2018